Product image of Linagliptin/Μetformin Sandoz (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linagliptin/Μetformin Sandoz

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linagliptin/Μetformin Sandoz (Metformin Hydrochloride, Linagliptin)

Linagliptin and Metformin Hydrochloride, the active ingredients in Linagliptin/Metformin Sandoz, are a DPP‑4 inhibitor and a biguanide presented as tablets for oral use. They treat type 2 diabetes mellitus in adults, often in combination with diet and exercise.

GNH India supplies Linagliptin/Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Sandoz Pharmaceuticals D.D.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin/Metformin Sandoz is an oral antidiabetic medication used to improve glycaemic control in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): provides glucose‑lowering effect when metformin alone is unsuitable.
  • Type 2 diabetes mellitus (add‑on to metformin): enhances glycaemic control in patients not reaching target with metformin alone.
  • Type 2 diabetes mellitus (combined with insulin): may allow reduction of insulin dose while maintaining control.

How It Works

  • Linagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), preventing degradation of endogenous incretin hormones and thereby enhancing glucose‑dependent insulin secretion. Metformin decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, resulting in reduced fasting and post‑prandial blood glucose levels.

Side Effects

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhoea: watery stools, usually transient.
  • Headache: mild tension‑type headache.
  • Upper respiratory tract infection: nasopharyngitis symptoms.
  • Abdominal discomfort: cramping or bloating.
  • Hypoglycaemia (when combined with sulfonylureas or insulin): sweating, tremor, confusion.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe allergic reactions: rash, angioedema, anaphylaxis.
  • Acute renal failure: sudden loss of kidney function.
  • Hepatic failure: jaundice, elevated liver enzymes.
  • Severe hypoglycaemia: neuroglycopenic symptoms requiring emergency care.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Renal function assessment: evaluate eGFR and avoid use in severe renal impairment.
  • Hepatic disease: use with caution in patients with liver dysfunction.
  • Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia.
  • Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
  • Drug interactions: review concomitant medications for potential additive effects.
  • Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Linagliptin/Metformin Sandoz may interact with several medicines.

Major Interactions (Avoid)

  • Sulfonylureas or insulin: increased risk of severe hypoglycaemia.
  • Iodinated contrast agents: may precipitate renal dysfunction with metformin.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin plasma levels.
  • Renin‑angiotensin system blockers: monitor renal function closely.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: can mask hypoglycaemia symptoms.
  • Thiazide diuretics: may attenuate glucose‑lowering effect.
  • Warfarin: monitor INR as metabolic changes can affect anticoagulation.

Frequently Asked Questions

Linagliptin/Metformin Sandoz is prescribed to improve blood‑glucose control in adults with type 2 diabetes mellitus, either as monotherapy when metformin alone is unsuitable or as add‑on therapy to existing antidiabetic regimens.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of incretin hormones. This enhances glucose‑dependent insulin secretion and reduces glucagon release, helping lower post‑prandial blood glucose levels.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions precisely.

Safety in pregnancy and lactation has not been established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

Enquiries can be submitted on the product page at gnhindia.com by specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other DPP‑4 inhibitors, linagliptin has a low risk of drug‑drug interactions because it is not primarily cleared by the kidneys. When combined with metformin, the fixed‑dose tablet offers convenient dosing versus separate agents, while providing complementary mechanisms of action.

Store the tablets at ambient temperature, below 25 °C, in the original container. Protect them from moisture and direct sunlight to maintain product stability throughout the shelf life.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include lactic acidosis (especially in patients with renal impairment), severe hypoglycaemia when combined with insulin or sulfonylureas, pancreatitis, and rare allergic reactions such as anaphylaxis. Patients should be educated to seek immediate medical attention if these events occur.

The combination is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to either component, or a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT